1. Home
  2. SCM vs LXEO Comparison

SCM vs LXEO Comparison

Compare SCM & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stellus Capital Investment Corporation

SCM

Stellus Capital Investment Corporation

HOLD

Current Price

$8.80

Market Cap

267.2M

Sector

Finance

ML Signal

HOLD

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

HOLD

Current Price

$4.37

Market Cap

369.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCM
LXEO
Founded
2012
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
267.2M
369.8M
IPO Year
2012
2023

Fundamental Metrics

Financial Performance
Metric
SCM
LXEO
Price
$8.80
$4.37
Analyst Decision
Hold
Strong Buy
Analyst Count
1
9
Target Price
$9.00
$18.44
AVG Volume (30 Days)
170.1K
731.1K
Earning Date
05-11-2026
05-06-2026
Dividend Yield
14.22%
N/A
EPS Growth
N/A
39.81
EPS
0.06
N/A
Revenue
N/A
$654,000.00
Revenue This Year
$0.33
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$149.17
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.43
$3.60
52 Week High
$15.39
$10.99

Technical Indicators

Market Signals
Indicator
SCM
LXEO
Relative Strength Index (RSI) 37.77 35.19
Support Level $8.43 N/A
Resistance Level $9.85 $7.90
Average True Range (ATR) 0.24 0.33
MACD -0.02 -0.04
Stochastic Oscillator 12.12 2.84

Price Performance

Historical Comparison
SCM
LXEO

About SCM Stellus Capital Investment Corporation

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm functions throughout the United States, and it generates revenue in the form of interest income on debt investments, capital gains, and distributions.

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Share on Social Networks: